Abstract: 3-W-Rifamycin SV and S compound, wherein W is a piperazin-1-yl radical of the formula ##STR1## wherein R.sup.1 and R.sup.2 are C.sub.1 -C.sub.4 alkyl and R.sup.3, R.sup.4 and R.sup.5 are hydrogen or C.sub.1 -C.sub.4 alkyl, or R.sup.2 together with R.sup.3 or R.sup.3 together with R.sup.4 are buta-1,3-dien-1,4-ylene, trimethylene or tetramethylene, each of which is unsubstituted or substituted by C.sub.1 -C.sub.4 alkyl, and R.sup.1, R.sup.4 and R.sup.5 or R.sup.1, R.sup.2 and R.sup.5 are hydrogen or C.sub.1 -C.sub.4 alkyl, and salts thereof, have long-term antituberculotic and antimicrobial activity.

Abstract: The present invention relates to a transdermal therapeutic system for the combined administration of oestrogens and gestagens. The therapeutic system consists of:(1) a closed outer layer which is impermeable to the constituents of the active ingredient formulation,(2) a reservoir containing essential constitutents of the active ingredient formulation and, optionally, a membrane,(3) an adhesive layer and(4) a peel-off protective layer on the adhesive layer.The system contains an oestrogen derivative in combination with a synthetic gestagen, and an agent that enhances percutaneous absorption.

Abstract: Compounds of the formula ##STR1## in which R.sub.1 represents acyl substituted by a thio, sulphinyl or sulphonyl group, A represents an optionally N-alkylated .alpha.-amino acid residue that is bonded N-terminally to R.sub.1 and C-terminally to the group --NR.sub.2 --, R.sub.2 represents hydrogen or lower alkyl, R.sub.3 represents hydrogen, lower alkyl, optionally etherified or esterified hydroxy-lower alkyl, cycloalkyl, cycloalkyl-lower alkyl, bicycloalkyl-lower alkyl, tricycloalkyl-lower alkyl, aryl or aryl-lower alkyl, R.sub.4 represents hydroxy or etherified or esterified hydroxy, R.sub.5 represents lower alkyl, optionally etherified or esterified hydroxy-lower alkyl, cycloalkyl, cycloalkyl-lower alkyl, bicycloalkyl, bicycloalkyl-lower alkyl, tricycloalkyl, tricycloalkyl-lower alkyl, aryl, aryl-lower alkyl, optionally substituted carbamoyl, optionally substituted amino, optionally substituted hydroxy, optionally substituted mercapto, sulphinyl or sulphonyl, and R.sub.

Abstract: The compounds of the formula ##STR1## in which one of the groups R.sup.1, R.sup.2 and R.sup.3 represents hydrogen, C.sub.1 -.sub.8 -alkyl, C.sub.3 -.sub.6 -cycloalkyl, phenyl optionally substituted by halogeno, C.sub.1 -.sub.4 -alkyl, C.sub.1 -.sub.4 -alkoxy and/or trifluoromethyl, or C.sub.7 -.sub.10 -phenylalkyl optionally substituted in the phenyl moiety by halogeno, C.sub.1 -.sub.4 -alkyl, C.sub.1 -.sub.4 -alkoxy and/or trifluoromethyl, and the other two are hydrogen, or salts thereof.These compounds have valuable pharmaceutical properties.

Abstract: 3-Substituted 4(1H)-pyridone compounds of formula ##STR1## wherein R.sub.1 is an unsubstituted or substituted hydrocarbon radical, X is a bond or a group of formula --O-- or --N(R.sub.3)--, wherein R.sub.3 is hydrogen or an unsubstituted or substituted hydrocarbon radical, and R.sub.2 is an unsubstituted or substituted hydrocarbon radical, or wherein R.sub.2 and R.sub.3, when taken together, are an unsubstituted or substituted divalent hydrocarbon radical, and wherein the other ring carbon atoms of the 4(1H)-pyridinone ring, independently of one another, are unsubstituted or substituted by an unsubstituted or substituted hydrocarbon radical or by etherified or esterified hydroxy, and salts of compounds of formula I with salt-forming properties, form chelate-type metal complexes, especially with trivalent metal ions, and can be used, for example, as pharmacologically active compounds.

Abstract: The invention relates to novel processes and intermediates for the preparation of 5-amino-4-hydroxyvaleric acid derivatives of the formula ##STR1## in which R.sup.1 represents hydrogen, optionally substituted alkyl, cycloalkyl, cycloalkyl-lower alkyl, aryl, aryl-lower alkyl or the radical of a natural amino acid, R.sup.2 represents hydrogen, optionally substituted alkyl, cycloalkyl, cycloalkyl-lower alkyl, aryl, aryl-lower alkyl, amino, hydroxy, mercapto, sulphinyl, sulphonyl or the radical of a natural amino acid, and R.sup.3 represents optionally substituted hydroxy or amino, by sigmatropic rearrangement of a suitable allyl ester, halolactonisation of the resulting .gamma.,.delta.-unsaturated acid or of a suitable derivative thereof, exchange of halogen for a nitrogen-containing nucleophile, opening of the lactone ring and freeing of the amino group. Compounds of the formula I are starting materials for the preparation of renin-inhibitors which have an anti-hypertensive action.

Abstract: Light-stabilized polymer microparticles, which contain at least one light stabilizer and free epoxy groups, and processes for the preparation of these microparticles by polymerization of suitable monomers, at least one of these monomers being an epoxide which contains at least one further reactive group, and at least part of the polymerization being carried out in the presence of at least one light stabilizer, are described. The polymer microparticles can be used in coating compositions which comprise a disperse phase, containing these particles, and a liquid continuous phase.Coatings and paints based on the compositions according to the invention are distinguished by improved weathering resistance, in particular high light stability.

Abstract: Composition of matter containing(a) a compound of the formula I ##STR1## in which A is one of the groups of the formulae ##STR2## in which B is --O--, --S--, --SO.sub.2 --, --N.dbd.N--, --CH.sub.2 --, --CH.dbd.CH--, ##STR3## --CONH--, --NHCONH--, or --CONHNHCO--, Q is --O-- or --NH-- and Z is --O-- or --S-- and R and R' are independently of each other hydrogen, halogen, C.sub.1 -C.sub.4 -alkyl, C.sub.1 -C.sub.4 -alkoxy or phenoxy, and(b) a compound of the formula II ##STR4## in which A' is as defined above for A, D is hydrogen, amino or a group of the formula III ##STR5## E is --O-- or --S--, T.sub.1, T.sub.2 and T.sub.3 independently of one another are chlorine or a group --ET', T' is a group of the formulae ##STR6## X.sup..sym. is H.sup..sym. or a group of the formulae M.sup.n.sym. /n or N.sup..beta. (R.sub.1)(R.sub.2)(R.sub.3)(R.sub.4), Mhu n.sym. is an n-valent metal cation, n is 1, 2 or 3, R.sub.1, R.sub.2, R.sub.3 and R.sub.4 are independently of one another hydrogen, C.sub.1 -C.sub.18 -alkyl, C.sub.

Abstract: Compounds of the formula ##STR1## in which R.sub.1 represents acyl substituted by a thio, sulphinyl or sulphonyl group, A represents an optionally N-alkylated .alpha.-amino acid residue that is bonded N-terminally to R.sub.1 and C-terminally to the group --NR.sub.2 --, R.sub.2 represents hydrogen or lower alkyl, R.sub.3 represents hydrogen, lower alkyl, optionally etherified or esterified hydroxy-lower alkyl, cycloalkyl, cycloalkyl-lower alkyl, bicycloalkyl-lower alkyl, tricycloalkyl-lower alkyl, aryl or aryl-lower alkyl, R.sub.4 represents hydroxy or etherified or esterified hydroxy, R.sub.5 represents lower alkyl, optionally etherified or esterified hydroxy-lower alkyl, cycloalkyl, cycloalkyl-lower alkyl, bicycloalkyl, bicycloalkyl-lower alkyl, tricycloalkyl, tricycloalkyl-lower alkyl, aryl, aryl-lower alkyl, optionally substituted carbamoyl, optionally substituted amino, optionally substituted hydroxy, optionally substituted mercapto, sulyhinyl or sulphonyl, and R.sub.

Abstract: Cephalin derivatives of the formula I ##STR1## in which R.sup.1 and R.sup.2 each represents, independently of the other, hydrogen or lower alkyl, R.sup.3 represents hydrogen, lower alkoxycarbonyl, carbamoyl or free or protected carboxy, R.sup.4 represents hydrogen or an aliphatic, aromatic, aromatic-aliphatic or cycloaliphatic radical, W represents hydrogen and Z represents a 1,2-dihydroxyethyl, 2-hydroxyethyl or hydroxymethyl group in which at least one hydroxy group is esterified by an aliphatic C.sub.6-30 -carboxylic acid or etherified by an aliphatic C.sub.6-30 -alcohol and in which the other hydroxy group, if present, is free, esterified by an aliphatic C.sub.2-30 -carboxylic acid or etherified by an aliphatic C.sub.1-30 -alcohol, or W represents hydroxymethyl or a hydroxymethyl group that is esterified by an aliphatic C.sub.6-30 -alcohol and Z represents a hydroxymethyl group that is esterified by an aliphatic C.sub.6-30 -carboxylic acid or etherified by an aliphatic C.sub.

Abstract: Novel hybrid interferons are produced which are derived from lymphoblastoid interferons .alpha.-2 and .alpha.-3 belonging to the interferon .alpha.B and .alpha.D groups, respectively. The novel hybrid interferons possess valuable antiviral and antiproliferative properties.

Abstract: The compounds of the formula (I) ##STR1## in which R.sub.1 is C.sub.1 -C.sub.8 -alkyloxy, allyloxy, allylamino, di(C.sub.1 -C.sub.4 -alkyl)amino, diallylamino, a 5-membered to 7-membered nitrogen containing heterocyclic group with the nitrogen atom linked to the triazine ring, or a group of the formula (II), ##STR2## R.sub.2 is hydrogen, O.sup.., OH, NO, CH.sub.2 CN, C.sub.1 -C.sub.8 -alkyl, allyl, benzyl, C.sub.1 -C.sub.8 -acyl, C.sub.1 -C.sub.18 -alkyloxy, C.sub.5 -C.sub.12 -cycloalkyloxy or OH-monosubstituted C.sub.2 -C.sub.4 -alkyl, R.sub.3 and R.sub.5 independently are hydrogen, C.sub.1 -C.sub.12 -alkyl,* monosubstituted by OH, by C.sub.1 -C.sub.4 -alkyloxy or by di(C.sub.1 -C.sub.4 -alkyl)amino, or a group of the formula (III) ##STR3## with R.sub.2 as defined above, R.sub.4 is hydrogen, C.sub.1 -C.sub.12 -alkyl or cyclohexyl and n is an integer from 2 to 6, are useful as light stabilizers, heat stabilizers and oxidation stabilizers for organic materials, in particular synthetic polymers. * C.sub.5 -C.

Abstract: Light-stabilized star polymer microparticles are described which are prepared with particular advantage by group transfer polymerization. The light stabilization is effected by carrying out at least a part step of the polymerization in the presence of a light stabilizer, for example a hindered amine or/and a UV absorber. With particular advantage, those light stabilizers are used which contain reactive groups in the molecule and, in this way, can be chemically incorporated into the polymer. The polymer microparticles show excellent light stability and are outstandingly suitable as constituents in coating compositions which can be processed, for example, to give coating films of high light stability.

Abstract: Corrosion inhibitors comprising(a) an imidazoline of the formula I ##STR1## in which R.sup.1 is hydrogen, C.sub.1 -C.sub.6 -hydroxyalkyl, C.sub.1 -C.sub.6 -aminoalkyl or C.sub.2 -C.sub.19 -carboxyalky or an ammonium or amine salt thereof and R.sup.2 is hydrogen, C.sub.1 -C.sub.17 -alkyl or C.sub.2 -C.sub.17 -alkenyl,(b) a heterocyclic polyacid of the formula II ##STR2## in which R.sup.3 is C.sub.2 -C.sub.6 -carboxyalkyl or an alkali metal, alkaline earth metal, ammonium or amine salt thereof,(c) at least one alkanolamine of the formula III ##STR3## in which R.sup.4 is C.sub.1 -C.sub.6 -hydroxyalkyl and R.sup.5 and R.sup.6, which can be identical or different, are hydrogen, C.sub.1 -C.sub.6 -alkyl or C.sub.1 -C.sub.6 -hydroxyalkyl, and(d) water are outstandingly suitable for the corrosion-inhibiting treatment of shaped iron and steel parts.

Abstract: A method of reducing the viscosity of asphaltenic crude oils by incorporating into said crude oil an effective viscosity reducing amount of an oil soluble organic compound having at least one oleophobic and hydrophobic fluoroaliphatic group, and optionally a low viscosity diluent, and compositions thereof.

Abstract: Rifamycin derivatives of formula ##STR1## wherein R is a radical of the formula ##STR2## in which R.sub.1 is an unsubstituted or substituted biphenylyl radical, and wherein X--X, Y--Y and Z--Z are each vinylene of the formula CH.dbd.CH, or wherein X--X and Y--Y are each ethylene of the formula CH.sub.2 --CH.sub.2 and Z--Z is ethylene or vinylene, and processes for the preparation thereof are described. These compounds can be used as antibacterial and antiviral medicaments.

Abstract: Mono- and di-saccharidyl derivatives that are linked via a bridge member to a cephalin derivative, of the formula I, and processes for their manufacture are described. ##STR1## In the formula, R.sup.1 represents (a) aldohexosyl, (b) D-aldohexosyl that is glycosidically linked in the 4- or the 6-position to D-aldohexosyl, (c) aldopentosyl, (d) 6-deoxyaldohexosyl or (e) 2-acetylamino-2-deoxy-D-aldohexosyl, it being possible for free hydroxy groups present in the radicals mentioned under (a) to (e) above to be peracetylated, X represents oxygen or sulphur, Y represents alkylene having up to 10 carbon atoms in which from 1 to 3 non-terminal methylene groups may be replaced by oxygen, by carbonylimino or by carbonyloxy, R.sup.2 represents hydrogen, carboxy, lower alkoxycarbonyl, benzyloxycarbonyl or carbamoyl, R.sup.3 represents hydrogen and R.sup.4 represents a 1,2-dihydroxy-ethyl, 2-hydroxy-ethyl or hydroxymethyl group in which at least one hydroxy group is esterified by an unsubstituted aliphatic C.sub.

Abstract: Aromatically substituted azacycloalkylalkanediphosphonic acids of the formula ##STR1## in which R represents an aromatically substituted azacycloaliphatyl radical that is bonded to the group alk by way of a nitrogen atom and that optionally contains an additional nitrogen atom, and alk represents a divalent aliphatic radical, and their salts, can be used for the treatment of illnesses that can be attributed to calcium metabolism disorders. They are manufactured, for example, by reacting a compound of the formulaR--alk--X.sub.3 (IV)in which X.sub.3 represents carboxy, carbamoyl or cyano, with phosphorus acid and phosphorus trichloride and in an intermediate of the formula ##STR2## obtained by starting from compounds of the formula IV in which X.sub.3 represents cyano or carbamoyl and by working up by hydrolysis, or in a salt thereof, replacing the amino group by hydroxy by treatment with nitrous acid.

Abstract: IgE binding factors (IgE-bfs) with IgE suppressor (IgE-SF) activity obtainable from human colostrum in an enriched form, a method for the prevention and/or the treatment of allergy by administering the IgE-bfs and pharmaceutical compositions comprising said IgE-bfs.

Abstract: Novel 4-acylresorcinol ethers of the formula ##STR1## in which R.sub.1 represents lower alkyl, R.sub.2 represents lower alkyl, lower alkenyl or lower alkynyl, R.sub.3 represents hydrogen, lower alkoxy, trifluoromethyl or halogen, alk represents an alkylene radical, one of the radicals R.sub.4, R.sub.5 and R.sub.7 is a group of the formula --NH--C(.dbd.O)--R.sub.8, a radical R.sub.4 or R.sub.5 that is other than a group of the formula --NH--C(.dbd.0)--R.sub.8 is a radical R.sub.9 and a radical R.sub.7 that is other than a group of the formula --NH--C(.dbd.0)--R.sub.8 is a radical R.sub.10, R.sub.6 represents hydrogen, lower alkyl, halogen, trifluoromethyl, optionally esterified or amidated carboxy, cyano or lower alkanoyl, R.sub.8 represents optionally esterified or amidated carboxy, or 5-tetrazolyl, R.sub.9 represents hydrogen, lower alkyl, lower alkoxy, halogen or trifluoromethyl, and R.sub.